Skip to main content

Table 1 Comparison of patient characteristics between CCLG and GPOH

From: Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92

  Number of patients (percentage) p value
CCLG GPOH
N = 210 N = 437
Gender
 Female 84 (40) 177 (40) 0.90
 Male 126 (60) 260 (60)
Age (approx quartiles) (years)
 0–9 34 (16) 94 (22) 0.17
 10–14 74 (35) 123 (28)
 15–19 58 (28) 115 (26)
 20–35 44 (21) 105 (24)
Primary site
 Central axis 84 (40) 236 (54) < 0.001 (0.004)
 Extremity 115 (55) 197 (45)
 Unknown 11 (5) 4 (1)
 Axial skeletal 26 (12) 89 (20)
 Spine 7 (3 30 (7)
 Pelvis 51 (24) 117 (27)
 Limb proximal 61 (29) 103 (23)
 Limb distal 54 (26) 94 (22)
 Unknown 11 (5) 4 (1)
Volume
 < 100 ml 57 (27) 117 (27) 0.48 (0.97)
 ≥ 100 ml 149 (71) 304 (69)
 Unknown 4 (2) 16 (4)
Metastases
 No 150 (71) 329 (75) 0.27 (0.41)
 Yesd 56 (27) 105 (24)
 Unknown 4 (2) 3 (1)
Histology
 Ewing’s sarcoma 140 (67) 261 (60) < 0.001 (< 0.001)
 Atypical Ewing’s 8 (4) 70 (16)
 PNET 43 (20) 101 (23)
 Othera 6 (3) 5 (1)
 Unknown 13 (6) 0 (0)
Risk group
 Standard (SR) 53 (25) 102 (23) 0.60
 High (HR) 157 (75) 335 (77)
Trial treatment
 SR-VACA 27 (13) 52 (12) 0.96
 SR-VAIA 26 (12) 50 (11)
 HR-VAIA 76 (36) 164 (38)
 HR-EVAIA 81 (39) 171 (39)
Histological responsec
 Good 52 (25) [58] 78 (18) [65] < 0.001 [0.33]
 Poor 37 (18) [42] 42 (10) [35]
 No surgery 103 (49) 111 (25)
 NAb 3 (1) 200 (46)
 Unknown 15 (7) 6 (1)
No. of chemotherapy cycles received
 1–4 18 (8.6) 26 (6.0) 0.32
 5–9 22 (10.5) 62 (14.2)
 10–13 36 (17.10 83 (19.0)
 14 131 (62.4) 254 (58.2)
 Unknown 3 (1.4) 12 (2.8)
  1. p values including unknown data; the p values in brackets exclude unknown data
  2. aOsteosarcoma or soft tissue
  3. bNA not applicable, i.e. patients with early radiotherapy before surgery
  4. cThe numbers in square brackets are based only on patients with a good or poor response
  5. dThe proportions of patients with bone or bone marrow metastases were similar: 8% GPOH and 5% CCLG